Dopaminergic Medication Modulates Learning from Feedback and Error-Related Negativity in Parkinson’s Disease: A Pilot Study by Chiara Volpato et al.
ORIGINAL RESEARCH
published: 24 October 2016
doi: 10.3389/fnbeh.2016.00205
Dopaminergic Medication Modulates
Learning from Feedback and
Error-Related Negativity in
Parkinson’s Disease: A Pilot Study
Chiara Volpato 1*, Sami Schiff 2, Silvia Facchini 3, Stefano Silvoni 1, Marianna Cavinato 1,
Francesco Piccione 1, Angelo Antonini 3 and Niels Birbaumer 1,4
1 Department of Behavioural Neuroscience, IRCCS Fondazione Ospedale San Camillo, Venice, Italy, 2 Department of
Medicine—DIMED, University of Padua, Padua, Italy, 3 Parkinson and Movement Disorders Unit, IRCCS Fondazione
Ospedale San Camillo, Venice, Italy, 4 Institute for Medical Psychology and Behavioural Neurobiology, University of Tübingen,
Tübingen, Germany
Edited by:
Angela Roberts,
University of Cambridge, UK
Reviewed by:
Carlos Tomaz,
University CEUMA, Brazil
Johan Alsio,
University of Cambridge, UK
*Correspondence:
Chiara Volpato
chiara.volpato@
ospedalesancamillo.net
Received: 13 June 2016
Accepted: 05 October 2016
Published: 24 October 2016
Citation:
Volpato C, Schiff S, Facchini S,
Silvoni S, Cavinato M, Piccione F,
Antonini A and Birbaumer N (2016)
Dopaminergic Medication Modulates
Learning from Feedback and
Error-Related Negativity in
Parkinson’s Disease: A Pilot Study.
Front. Behav. Neurosci. 10:205.
doi: 10.3389/fnbeh.2016.00205
Dopamine systems mediate key aspects of reward learning. Parkinson’s disease (PD)
represents a valuable model to study reward mechanisms because both the disease
process and the anti-Parkinson medications influence dopamine neurotransmission.
The aim of this pilot study was to investigate whether the level of levodopa differently
modulates learning from positive and negative feedback and its electrophysiological
correlate, the error related negativity (ERN), in PD. Ten PD patients and ten healthy
participants performed a two-stage reinforcement learning task. In the Learning Phase,
they had to learn the correct stimulus within a stimulus pair on the basis of a
probabilistic positive or negative feedback. Three sets of stimulus pairs were used.
In the Testing Phase, the participants were tested with novel combinations of the
stimuli previously experienced to evaluate whether they learned more from positive or
negative feedback. PD patients performed the task both ON- and OFF-levodopa in
two separate sessions while they remained on stable therapy with dopamine agonists.
The electroencephalogram (EEG) was recorded during the task. PD patients were less
accurate in negative than positive learning both OFF- and ON-levodopa. In the OFF-
levodopa state they were less accurate than controls in negative learning. PD patients
had a smaller ERN amplitude OFF- than ON-levodopa only in negative learning. In the
OFF-levodopa state they had a smaller ERN amplitude than controls in negative learning.
We hypothesize that high tonic dopaminergic stimulation due to the dopamine agonist
medication, combined to the low level of phasic dopamine due to the OFF-levodopa
state, could prevent phasic “dopamine dips” indicated by the ERN needed for learning
from negative feedback.
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INTRODUCTION
The dopamine system plays a crucial role in reinforcement learning. In particular,
electrophysiological studies in primates have shown that reward elicits phasic dopamine increases,
whereas aversive feedback leads to phasic dopamine decreases in midbrain dopamine neurons.
Thus, reduction of phasic dopamine responses, due to a decrease or an excessive increase of
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dopamine level, could negatively affect prediction error and,
consequently, impair reinforcement learning (Schultz, 2002;
Montague et al., 2004).
Parkinson’s disease (PD) is a valuable model to study
reinforcement learning because of the dysfunction involving
dopaminergic basal ganglia-prefrontal cortex circuits. In PD loss
of dopamine determines modification of both tonic and phasic
aspects of dopamine neurotransmission affecting reinforcement
learning (Frank et al., 2004). Dopaminergic medication has
been reported to produce positive effects on some cognitive
impairments (i.e., cognitive flexibility) and negative effects on
others, such as reward learning (Swainson et al., 2000; Cools
et al., 2001, 2003, 2006; Bódi et al., 2009; Peterson et al.,
2009; Shiner et al., 2012). According to Frank (2005), in
PD two different neural populations in the striatum respond
in opposite directions to dopaminergic medication. Increased
levels of dopamine activate the direct ‘‘Go’’ pathway (via D1
excitatory receptors) improving learning from positive feedback
and suppress the indirect ‘‘No-Go’’ pathway (via D2 inhibitory
receptors) affecting learning from negative feedback. More
recently, Moustafa et al. (2013) proposed a reinforcement
learning model that takes into account the different effects
of levodopa and dopamine agonists on tonic and phasic
dopamine levels, determining selective effects on reward learning
processes. The model assumes that levodopa acts on both
D1 and D2 dopamine receptors whereas dopamine agonists
have a high affinity for D2 receptors. Moreover, phasic
dopamine activates D1 receptors, whereas tonic dopamine
activates D2 receptors only. Thus, both levodopa and dopamine
agonists restore tonic activation whereas only levodopa, but
not dopamine agonists, restores phasic activity. The model,
therefore, predicts that levodopa and dopamine agonists could
differentially affect reward learning. Levodopa enhances reward
learning via phasic dopamine activity whereas dopamine
agonists impair reward learning by increasing tonic dopamine
activity, preventing phasic responses from being effective. These
assumptions are substantiated by studies on healthy people
reporting that administration of dopamine agonists negatively
affects reinforcement-based learning (Frank and O’Reilly, 2006;
Santesso et al., 2009).
The error related negativity (ERN) could have a peculiar
function in reinforcement learning. A prevailing hypothesis
holds that the ERN reflects midbrain dopamine system activity
caused by dips in dopamine 50–100 ms after incorrect responses.
The midbrain dopamine system conveys this error signal to
the anterior cingulate cortex, where the signal is used to
improve task performance (Falkenstein et al., 1991; Gehring
et al., 1993; Holroyd and Coles, 2002). Phasic dopaminergic
activity seems to be particularly sensitive to the alteration
of dopamine levels affecting learning mechanism. In PD the
alteration of tonic and phasic dopamine activity could affect
ERN (Falkenstein et al., 2001; Holroyd et al., 2002; Beste et al.,
2009) and learning processes (Frank et al., 2004). On the
other hand, dopaminergic medication, in particular dopamine
agonists, could determine a negative effect on learning. Indeed,
high tonic activity of dopamine due to dopamine agonists could
disturb the equilibrium of phasic activity (such as ‘‘dopamine
dips’’ associated with the ERN) needed for reinforcement
learning effects (Cools et al., 2001). Nevertheless, previous
studies in PD patients showed that the ERN is not affected by
dopaminergic treatment (Stemmer et al., 2007; Willemssen et al.,
2008).
According to themodel of Frank et al. (2005), as the difference
in positive/negative feedback learning depends on different levels
of dopamine in the basal ganglia, the ERN should be larger
for low levels than high levels of dopamine. Dopaminergic
medication could excessively increase the level of dopamine by
preventing ‘‘dopamine dips’’ (ERN) associated with the error
detection determining a specific impairment in learning from
negative feedback. In theirmodel, however, they refer to a general
effect of dopaminergic medication and do not distinguish the
possible differential effect of levodopa and dopamine agonists.
On the other hand, according the model of Moustafa et al.
(2013), only levodopa, but not dopamine agonists, should affect
phasic dopamine activity, including ‘‘dopamine dips’’ resulting in
the ERN.
In this pilot study, learning from feedback and the ERN
were assessed in a small sample of PD patients performing
a probabilistic learning task (Frank et al., 2004, 2005). As
first objective we were interested to investigate the effect of
phasic dopamine release related to levodopa bioavailability on
reinforcement learning. Thus we tested PD patients in two
different conditions: (1) ON-levodopa (within 1 h of levodopa
therapy); and (2) OFF-levodopa (within 30 min before the next
levodopa dose). From an ethical point of view, this type of
measurement of the OFF-state avoided PD patients discomfort
determined by forced full wash out from medication, and in our
specific case, allowed patients to continue their rehabilitation
program. Moreover, the stable level of dopamine agonists (all
extended release formulations) resulting in tonic dopaminergic
stimulation, allows to isolate the assumed (phasic) effect
of levodopa on reinforcement learning without concomitant
interference from the consequence of additional tonic level
changes (Moustafa et al., 2013). Thus, we could expect that
reward learning is facilitated in the ON-levodopa state and it
is impaired in the OFF-levodopa state. In the same way, the
ERN amplitude should be reduced in the OFF-levodopa state,
because the ERN is affected by the lack of phasic bursts of
dopamine neurons and loses the capacity to indicate violation of
positive and negative expectations (Schultz, 2002; Moustafa et al.,
2013). However, a further study in which both the treatment
with dopamine agonists and levodopa aremanipulated separately
is needed to discern the specific effect of one or the other
substance.
MATERIALS AND METHODS
Participants
Ten PD patients (recruited at San Camillo Hospital of Venice)
and 10 healthy participants matched for age and education
were enrolled in the study. PD was diagnosed according to the
United Kingdom PD Society brain bank diagnostic criteria for
PD (Hughes et al., 1992); symptoms were evaluated with the
Unified PD Rating Scale (Fahn and Elston, 1987) when patients
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were in OFF-levodopa state, and PD was staged according
to the Hoehn-Yahr Scale (Hoehn and Yahr, 1967). Exclusion
criteria were: (1) other neurological or mental disorder except
for mild depressive symptoms (Beck Depression Inventory
score (BDI) >13 (Beck et al., 1961); (2) Mini Mental State
Examination (MMSE) score <24 (Magni et al., 1996); (3)
advanced symptoms (stage IV or V in the Hoehn-Yahr Scale);
(4) deep brain stimulation implant or continuous infusion
pump. All patients took levodopa and nine took also dopamine
agonists (extended release formulations) and they were stable
on their medication dose for at least 2 months (Table 1).
The study was conducted in accordance with the Declaration
of Helsinki and was approved by the local Research Ethics
Committee.
Procedures
The PD patients were tested in two experimental conditions
separated by a minimum of 7 days: (1) within 1 h of levodopa
therapy, when they experienced the maximum therapeutic effect
of medication (ON-levodopa) and (2) within 30 min before
the next levodopa dose, when they experienced the minimum
therapeutic effect of medication (OFF- levodopa; Nombela et al.,
2012).
Task
We used a probabilistic learning task consisting of a learning
phase and a testing phase (Frank et al., 2004, 2005). The stimuli
were pairs of colored pictures representing common objects
(International Affective Picture System; Lang et al., 2008). The
stimuli were delivered by a software for experimental psychology
designs (E-prime).
In the Learning Phase, three different stimulus pairs (AB,
CD, EF) were presented in random order on the screen of a
computer. The stimuli remained on the screen for 2500 ms.
A fixation point was presented during the inter-trial interval
(250–750 ms). Participants were required to identify the correct
object in the pair of stimuli by pressing the key on the left side
keyboard (Z) when they chose the stimulus on the left of the
screen, or the key on the right side of the keyboard (M) when
they chose the stimulus on the right of the screen. A probabilistic
TABLE 1 | Demographic and clinical data of sample.
Parameters Parkinson’s
disease patients
Healthy
controls
Gender (m/f) 7/3 4/6
Age (y) 56.3 (3.24) 57.9 (7.5)
Education (y) 12.0 (4.24) 13.1 (4.14)
Disease duration (y) 8.6 (3.8) -
Unified Parkinson’s Disease Rating Scale III 26.8 (15.81) -
Hoehn-Yahr Scale 1.95 (0.15) -
Levodopa equivalent dose (mg) 792.5 (450.0) -
Dopamine agonists equivalent dose (mg) 198.1 (145.4) -
Mini Mental State Examination 29.2 (1.0) 28.9 (1.37)
Beck Depression Inventory 8.8 (4.8) 9.7 (4.23)
Table represents mean (standard deviation) of clinical and demographic data of
Parkinson’s disease patients and healthy controls.
visual feedback followed the choice to indicate whether it was
correct or incorrect: a green ‘‘V’’ for a correct response and a
red ‘‘X’’ for an incorrect response. In the AB pair, stimulus A
was followed by a positive feedback in 80% and by a negative
feedback in 20% of the trials, whereas stimulus B was followed
by a negative feedback in 80% and by a positive feedback in
20% of trials. In CD pairs, stimulus C was followed by a positive
feedback in 70% of the trials and by a negative feedback in 30%
of the trials, whereas stimulus D was followed by a negative
feedback in 70% of the trials and a positive feedback in 30% of
the trials. In the EF pair, stimulus E was followed by a positive
feedback in 60% of the trials and by a negative feedback in
40% of the trials whereas stimulus F was followed by a negative
feedback in 60% of the trials and by a positive feedback in
40% of the trials. When the participants exceeded the stimulus
presentation time limit, the message ‘‘too late!’’ appeared on
the screen and the trial was excluded from the analysis. Three
blocks of 60 stimuli were performed. The trials were presented
in a randomized order. During the Learning Phase, participants
learned to choose stimuli A, C and E, which were followed more
frequently by a positive feedback and to avoid stimuli B, D and F,
which were followed more frequently by a negative feedback. It
was also explained that the correct identification of the stimulus
did not follow any logic beyond the feedback. To familiarize
participants with the task, they were engaged in a preliminary
practice block.
Immediately after, the Testing Phase followed to verify
whether participants learned more from positive vs. negative
feedback. For this purpose participants were tested with novel
combinations of stimuli in a random sequence (AC, AD, AE,
AF, BC, BD, BE, BF) in addition to the same stimulus pairs
used in the Learning Phase. In the novel combinations, the
stimulus that wasmore frequently followed by a positive feedback
(A) in the Learning Phase and the stimulus that was more
frequently followed by a negative feedback (B) in the Learning
Phase were paired to one of the other stimuli (C, D, E, F).
According to the principle of generalization of learning, in
the novel combinations participants should tend to choose
stimulus A and to avoid stimulus B. Accuracy was defined
as the choice of A in AC, AD, AF, AE, AF pairs and the
avoidance of B in BC, BD, BE, BF pairs. The trials were
presented in a randomized order. Patients were instructed to
follow their instinct in choosing the correct stimulus, since in
the Testing Phase they did not receive any feedback. As in the
Learning Phase, the participants were under time pressure. They
had to respond within 2500 ms of stimulus presentation time
and if they exceeded that time limit, the message ‘‘too late!’’
appeared on the screen. Also in the Testing Phase, participants
performed a short practice block to familiarize themselves with
the task. Accuracy was defined as the choice of A and the
avoidance of B.
Two parallel versions of the task including different stimuli
were administered during ON- and OFF-levodopa medication
to avoid a repetition learning effect. The two versions of the
task were counterbalanced between the ON- and OFF-levodopa
condition. Moreover, the order of the ON- and OFF-levodopa
condition was counterbalanced across patients.
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Event-Related Potential Recording and
Analysis
During task performance, the electroencephalogram (EEG) was
recorded from a 29-electrode cap with a standard 10–10 position
connected to an amplifier (Neuroscan, Sterling, VA, USA). The
EEG signal was referenced to Fpz. The vertical and horizontal
electrooculograms were recorded from electrodes placed below
the right eye and on the outer canthi of the right eye. Electrode
impedances were kept below 10 kO. The EEG data were sampled
at 500 Hz, amplified and filtered through a bandpass of 0.1–70
Hz. The EEG signal was processed using a MATLAB toolbox
(EEGLAB v10.2.5.8b, Delorme and Makeig, 2004). The signal
was low-pass filtered at 30 Hz. Ocular artifacts were removed
using a MATLAB toolbox (Gratton et al., 1983). Response-
locked event-related potentials were computed within epochs
starting 800 ms prior to the response and lasting 500 ms after
the response and were baseline corrected with respect to the
first 100 ms of these epochs. ERN was defined as the peak-
to-peak voltage difference between the negative peak within
150 ms after the response and the preceding positive peak
(Falkenstein et al., 1991; Gehring et al., 1993). Analyses focused
on signals from the Cz electrode where the ERN was easily
detectable. Epochs were extracted and averaged for the following
conditions: errors in positive learning items (avoidance of the
A stimulus in AC, AD, AE, AF pairs) and errors in negative
learning items (choice of the B stimulus in the BC, BD, BE, BF
pairs) and for each group: controls, PD OFF-levodopa and PD
ON-levodopa.
Data Analysis
Since we were interested in investigating whether dopaminergic
medication differently affects learning from positive vs. negative
feedback in PD, we focused the analysis on the accuracy of
novel pair combinations in the Testing Phase and the ERN
associated to errors committed in these trials. Novel pair
combinations provide the amount of learning from positive
feedback (number of times the subjects chose the stimulus A)
vs. negative feedback (number of times the subject avoided the
stimulus B). Moreover, we analyzed the event-related potential
associated to the detection of avoidance of A and the choice
of B errors in the Testing Phase: the ERN. Indeed, as reported
by Frank et al. (2005) in their study on healthy subjects the
size of the ERN could express the degree to which participants
learn more from the negative vs. the positive consequence of
their decisions (feedback). Statistical analysis was performed
with the IBM SPSS Statistics software package. Kolmogorov-
Smirnov tests confirmed the assumptions of normality of
all the variables; thus we decided to use parametric testing.
Overall accuracy and overall ERN within the PD group (ON
vs. OFF) was compared with a Paired Sample T test. A
repeated measures analysis of variance (ANOVA) with two
within factors ‘‘levodopa state’’ (ON vs. OFF) and ‘‘learning’’
(positive vs. negative) was applied to compare accuracy and
ERN associated to positive or negative feedback within the
PD group ON- and OFF-levodopa. The comparison of overall
accuracy and overall ERN between groups (CTRL vs. PD) was
performed with an Independent Sample T test. A repeated
measures ANOVA with a within factor ‘‘learning’’ (positive
vs. negative) and a between factor ‘‘group’’ (controls vs. PD
ON-levodopa; controls vs. PD-OFF levodopa) was performed to
compare accuracy and ERN associated to positive vs. negative
feedback.Multiple comparisons were performed with Bonferroni
correction.
RESULTS
Demographic and Clinical Data
No statistically significant differences were found between
PD patients and controls with respect to socio-demographic
characteristics, MMSE and BDI scores (Table 1).
Behavioral Data
The statistical analysis showed no significant difference between
PD patients ON-levodopa (mean = 60%, SD = 17%) and OFF-
levodopa (mean = 64%, SD = 25%; t = 0.519, p = 0.616)
in overall accuracy. The overall performance of controls
(mean = 80%, SD = 16%) was better than that of PD patients
OFF-levodopa (t = 2.470, p = 0.024) and PD patients ON-
levodopa (t = 2.408, p = 0.027). However in the AB condition,
all the participants reached a high level of accuracy (controls:
mean = 86%, SD = 13%; PD ON-levodopa: mean = 78%,
SD= 21%; PD OFF-levodopa: mean= 73%, SD= 22%).
Testing Phase—Within Patients Analysis
Paired Samples T tests did not show any significant difference
between PD patients ON-levodopa and PD patients OFF-
levodopa in overall accuracy. To evaluate positive vs. negative
learning we calculated the percentage of responses where subjects
chose the stimulus A and the percentage of times the subjects
avoided the stimulus B. The repeated measures ANOVA showed
a significant effect of ‘‘Learning’’ (F(1,9) = 17.417, p = 0.002).
Multiple comparisons (Bonferroni corrected) revealed that the
performance of PD patients was less accurate in negative
learning (OFF-levodopa: mean= 35%, SD= 26%; ON-levodopa:
mean = 44%, SD = 22%) than positive learning (OFF-levodopa:
mean= 79%, SD= 12%; ON-levodopa: mean= 74%, SD= 23%)
both OFF-levodopa (p = 0.003) and ON-levodopa (p = 0.038;
Figure 1).
Testing Phase—Between Subjects Analysis
Independent Sample T test did not show any significant
difference between ON-levodopa (mean = 60%, SD = 10%) and
OFF-levodopa PD patients (mean= 58%, SD= 9%) and healthy
controls (mean = 69%, SD = 16%) in overall accuracy. The
comparison between controls and PD patients OFF-levodopa
revealed a significant effect of ‘‘Learning’’ (F(1,18) = 18.784,
p = 0.000) indicating a better performance in positive learning
than negative learning, ‘‘Group’’ (F(1,18) = 4.740, p = 0.043)
indicating a better performance in healthy controls than PD
OFF-levodopa. A significant ‘‘Learning × Group’’ interaction
was also found (F(1,18) = 4.656, p= 0.045). Multiple comparisons
(Bonferroni corrected) showed that PD patients OFF-levodopa
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(mean = 35%, SD = 26%) were less accurate than controls
(mean = 63%, SD = 23%) in negative learning (p = 0.047)
and PD patients OFF-levodopa were worse in negative learning
(mean = 35%, SD = 26%) than positive learning (mean = 79%,
SD = 12%; p < 0.001). The comparison between controls
and PD patients ON-levodopa revealed a significant effect
of ‘‘Learning’’ (F(1,18) = 10.050, p = 0.005) indicating a
better performance in positive learning than negative learning
(Figure 1).
Event-Related Potential Data
Testing Phase—Within Subjects Analysis
Paired Samples T tests did not show any significant difference
between PD patients ON-levodopa and PD patients OFF-
levodopa in the overall ERN. Repeated measures ANOVA
showed a significant effect of ‘‘Levodopa’’ (F(1,9) = 24.830,
p = 0.002) indicating a lower ERN amplitude in the OFF-
levodopa state. Multiple comparisons (Bonferroni corrected)
showed that PD patients OFF-levodopa (mean = 2.18 µV,
SD = 1.33 µV) had a reduced ERN amplitude compared
to ON-levodopa (mean = 3.95 µV, SD = 2.76 µV;
p = 0.000) in their choice of B errors (p = 0.010;
Figure 2).
Testing Phase—Between Subjects Analysis
Independent Sample T tests did not reveal any significant
difference between PD patients ON-levodopa (mean = 2.71 µV,
SD = 2.01 µV) and OFF-levodopa (mean = 2.10 µV,
SD = 1.23 µV) and healthy controls (mean = 3.46 µV,
SD = 1.83 µV) in overall amplitude. The comparison between
healthy participants and PD patients OFF-levodopa (repeated
measures ANOVA) showed a significant effect of ‘‘Group’’
(F(1,18) = 5.193, p = 0.039) indicating a lower ERN amplitude in
PD patients OFF-levodopa than controls. Multiple comparisons
(Bonferroni corrected) showed that PD patients OFF-levodopa
(mean = 2.18 µV, SD = 1.33 µV) had a significantly reduced
ERN compared to controls (mean = 3.75 µV, SD = 2.36 µV) in
their choice of B errors (p = 0.035). The comparison between
FIGURE 1 | The plot shows the percentage (%) of correct responses in
the Testing Phase. Negative Learning = percentage of avoidance of B
responses; Positive Learning = percentage of choice of A responses.
PD, Parkinson’s disease. ∗ Indicates significant difference (p < 0.05).
healthy controls and PD patients ON-levodopa showed no
significant effect (Figure 2).
FIGURE 2 | Grand-average of response-locked event-related
potentials (ERPs) to error and correct trials in (A) controls, (B) PD
patients ON-levodopa and (C) PD patients OFF-levodopa at Cz. PD,
Parkinson’s disease.
Frontiers in Behavioral Neuroscience | www.frontiersin.org 5 October 2016 | Volume 10 | Article 205
Volpato et al. Dopamine Modulates PD Reinforcement Learning
DISCUSSION
In the behavioral results, we found no significant difference on
overall accuracy between ON- and OFF-levodopa conditions.
However, when we analyzed separately learning from positive
vs. negative feedback, we found that performance of PD patients
both ON- and OFF-levodopa was worse in learning from
negative than positive feedback. Moreover, this difference was
more pronounced in the OFF-levodopa condition, although it
did not reach statistical significance. One possible explanation
is that during the OFF-levodopa state, phasic dopamine dips
associated to error detection are reduced because of the low
level of levodopa. Moreover, dopamine agonists, in contrast
to levodopa, tonically stimulate dopamine receptors preventing
dips in dopamine transmission significantly impairing negative
feedback learning (van Eimeren et al., 2009a). On the other
hand, in the ON-levodopa state, a high level of levodopa
enhanced phasic activity, improving learning both from positive
and negative feedback (Schultz, 2002; Frank et al., 2004;
Moustafa et al., 2013). It could be argued that the level of
levodopa seems to have no modulatory effect on learning
based on positive feedback since PD patients showed a
performance similar to that of the controls both ON-levodopa
and OFF-levodopa. However, OFF-levodopa PD patients were
not completely washed out from levodopa medication and the
minimum level of levodopa could have been high enough to
ensure a sufficient phasic activity to sustain positive feedback
learning.
The electrophysiological results support, at least in part,
the behavioral data. The overall ERN amplitude did not
differ among controls, ON-levodopa and OFF-levodopa PD
patients. Analyzing separately ERN responses associated with
the avoidance of the A stimulus (positive learning errors)
vs. the choice of the B stimulus (negative learning errors),
we found an effect of medication with the ERN amplitude
associated to choice of B errors significantly reduced in the
OFF-levodopa compared to the ON-levodopa state. Between-
subjects analyses demonstrated also that the ERN amplitude
associated with the choice of B errors was reduced in OFF-
levodopa PD patients in comparison with controls. As for
behavioral results, it could be assumed that the low level of
levodopa negatively impacted on phasic activity rendering
the ERN less sensitive to errors, and in particular to errors
associated with negative learning. Moreover, persisting tonic
stimulation of dopamine receptors—as with dopamine
agonist medication—could therefore prevent dopamine
dips and consequently reduce the ERN amplitude. On the
other hand, when PD patients were in the ON-levodopa
state, the high level of levodopa enabled phasic activity of
mesencephalic dopamine neurons enhancing elicitation of the
ERN.
In summary, we hypothesize that during the OFF-levodopa
state, dopamine phasic activity (burst and dips) is reduced,
causing an impairment in learning both from positive and
negative feedback and a reduction of ERN amplitude to
errors associated with both negative and positive learning.
However, OFF-levodopa, the patients continue to experience
the effect of dopamine agonists (via D2 receptors), determining
a reduction of dopamine dips necessary for learning from
negative feedback. Thus, in the OFF-levodopa state, learning
from negative feedback and the ERN associated with negative
errors are particularly affected. On the other hand, during
ON-levodopa, both D1 and D2 receptors were activated. The
activation of D1 receptors maintains dopamine phasic activity
(both burst and dips) necessary for learning from feedback (both
positive and negative), mitigating the effect of the dopamine
agonists on the D2 receptors. However, these conclusions are
weakened by the lack of a completely medication free group
of PD patients. Since only the level of levodopa, but not the
level of dopamine agonists has been manipulated, the hypothesis
of a negative effect of dopamine agonists on learning from
negative feedback and the ERN associated with choice of B
errors needs to be confirmed by further studies in which both
treatment with dopamine agonists and levodopa are manipulated
to definitely discern the specific effect of one or the other
substance.
The results obtained in this pilot study are in part in
contrast with those previously reported by Frank et al. (2004,
2005). However, in our study, differently from Frank et al.
(2004), patients were stable on dopamine agonist treatment.
As mentioned above, impaired learning from negative feedback
in the ON- and OFF-levodopa state could be, at least in
part, attributable to dopamine agonists. Dopamine agonists,
indeed, maintain a high tonic activity of dopamine neurons,
preventing phasic response from being effective. A specific
negative effect of dopamine agonists on punishment was
previously reported in studies on learning in PD. Bódi et al.
(2009) found that dopamine agonists positively affect reward
processing whereas they impair punishment processing in never
medicated PD patients. Cools et al. (2006) demonstrated that
dopaminergic medication, and in particular the dopamine
agonist pramipexole, impaired probabilistic and concurrent
reversal learning in tasks where reversals were signaled by
unexpected punishment in mild PD patients. According to
the model of Frank (2005), phasic ‘‘dopamine dips’’ associated
with error detection (ERN) are particularly vulnerable to the
excessive dopamine levels following dopaminergic medication.
When the dopamine level is too high because of the medication,
‘‘dopamine dips’’ are reduced leading to a selective impairment
in learning from punishment. In line with these hypotheses,
studies on impulse control disorder in PD have associated
these behavioral defects with dopamine agonist treatment
(Dodd et al., 2005; Antonini and Cilia, 2009; van Eimeren
et al., 2009a; Cilia et al., 2011). Dopamine agonists contribute
to the dysregulation of mesocortical dopaminergic pathways
involved in the modulation of reward, positive vs. negative
reinforcement learning, motivation, memory, inhibitory control
and decision-making, and are thus closely implicated in impulse
control and modulation of reward-seeking behaviors. Dopamine
agonists, thus, could make PD patients less sensitive to negative
reinforcement promoting errors based on a failure of learning
from the negative consequences of their actions. Concordant
with this clinical evidence Zalocusky et al. (2016) identified
the role of the dopamine receptor type-2 in the nucleus
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accumbens in signaling unfavorable outcomes from the recent
past at a time appropriate for influencing subsequent decisions.
Moreover, they demonstrated that the systemic administration
of the dopamine agonist pramipexole altered risk-preference
in rats, increasing risk-seeking in a dose-dependent manner.
In other words, dopamine agonists seem to alter the activity
of D2 receptors in the nucleus accumbens disabling them to
adequately signal negative outcomes. This assumption is also
strengthened by functional imaging studies that examined the
effect of dopamine agonists on neurofunctional activity related to
reinforcement learning processes (van Eimeren et al., 2009a,b).
Using functional magnetic resonance imaging, van Eimeren
et al. (2009b) found that dopamine agonists (pramipexole)
specifically changed activity of the orbitofrontal cortex in two
ways that were both associated with increased risk taking in
an out-of-magnet task. They propose that dopamine agonists
prevent pauses in dopamine transmission and thereby impair the
negative reinforcing effect of losing.
This result, if replicated, offers an interesting new possibility
to interpret the differential effect of levodopa on behavior
and cortical processing in PD: if the primary deficiency in
the presence of a stable tonic dopamine level (or stable
dopamine agonist level) consists of a reduced behavioral capacity
for avoidance probably caused by impaired limbic- (anterior
cingulate cortex) fronto-cortical processing of negative feedback
reflected in the attenuated ERN, then psychopathological high
risk behavior such as pathological gambling may be the
consequence (van Eimeren et al., 2009a).
A possible limit of this study is that measuring the ERN
during performance of the probabilistic learning task may seem
inappropriate because of the uncertainty of response correctness.
During the Learning Phase of the task the participants have
formed a representation of what was an error or a correct
response on the basis of probabilistic feedback. Hence, with
different probability the same trial could be associated both
to a positive and a negative feedback. It is likely that in the
Testing Phase the participants judged some correct responses
as errors, and vice versa, did not detect some errors. As
demonstrated by previous studies (Pailing and Segalowitz,
2004; Frank et al., 2005), the ERN is elicited also when the
response correctness is uncertain. In this condition, the ERN
could be attenuated: if the ERN results from mismatches
occurring during the response-comparison process, uncertainty
could influence the outcome of the comparison process and,
in some cases, the ERN mismatch signal would not occur,
and the size of the ERN could be smaller in the averaged
waveform (Pailing and Segalowitz, 2004). We believe that the
question of uncertainty of response correctness is important
but not critical for the interpretation of our findings. An ERN,
indeed, was detectable in each group and condition and it was
significantly reduced in PD patients OFF-levodopa during errors
associated with negative learning. Regardless of the uncertainty
of the response correctness, these results clearly indicate a
selective effect to negative feedback only in PD patients OFF-
levodopa.
Finally, because this is a pilot study with a small sample size,
the results should be interpreted with caution, and further studies
are needed to support our conclusions.
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